| Literature DB >> 31886867 |
Csaba Bödör1, Donát Alpár1, Dóra Marosvári1, Bence Galik2, Hajnalka Rajnai1, Bence Bátai1, Ákos Nagy1, Béla Kajtár3, Adrienn Burján3, Beáta Deák4, Tamás Schneider4, Hussain Alizadeh5, András Matolcsy1, Sebastian Brandner6, James Storhoff7, Ning Chen7, Mingdong Liu7, Nadeem Ghali8, Irén Csala9, Attila G Bagó10, Attila Gyenesei2, Lilla Reiniger1,11.
Abstract
Primary central nervous system lymphomas (PCNSL) are aggressive non-Hodgkin lymphomas affecting the central nervous system (CNS). Although immunophenotyping studies suggested an uniform activated B-cell (ABC) origin, more recently a spectrum of ABC and germinal center B-cell (GC) cases has been proposed, with the molecular subtypes of PCNSL still being a matter of debate. With the emergence of novel therapies demonstrating different efficacy between the ABC and GC patient groups, precise assignment of molecular subtype is becoming indispensable. To determine the molecular subtype of 77 PCNSL and 17 secondary CNS lymphoma patients, we used the NanoString Lymphoma Subtyping Test (LST), a gene expression-based assay representing a more accurate technique of subtyping compared with standard immunohistochemical (IHC) algorithms. Mutational landscapes of 14 target genes were determined using ultra-deep next-generation sequencing. Using the LST-assay, a significantly lower proportion (80% vs 95%) of PCNSL cases displayed ABC phenotype compared with the IHC-based characterization. The most frequently mutated genes included MYD88, PIM1, and KMT2D. In summary, we successfully applied the LST-assay for molecular classification of PCNSL, reporting higher proportion of cases with GC phenotype compared with IHC analyses, leading to a more precise patient stratification potentially applicable in the diagnostic algorithm of PCNSL.Entities:
Keywords: Brain lymphoma; Molecular subtype; Mutation profiling; Primary central nervous system lymphomas (PCNSL)
Mesh:
Year: 2020 PMID: 31886867 DOI: 10.1093/jnen/nlz125
Source DB: PubMed Journal: J Neuropathol Exp Neurol ISSN: 0022-3069 Impact factor: 3.685